Progesterone Receptor Antagonists
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Since the discovery of the progesterone receptor antagonist mifepristone, numerous additional compounds, which display a spectrum of biological actions ranging from full antagonist to those with mixed agonist/antagonist activity, have been synthesized. The latter are referred to as selective progesterone receptor modulators. Long-term administration of these agents is associated with an antiproliferative action on the endometrium as well as amenorrhea and often inhibition of ovulation. Thus far, the majority of clinical data have been obtained with mifepristone but studies are currently underway with other compounds. These compounds have application in the treatment of uterine myoma, endometriosis, dysfunctional uterine bleeding, as potential contraceptives and in steroid responsive tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
LAUE, L., LOTZE, M. T., CHROUSOS, G. P., BARNES, K., LORIAUX, D. L., & FLEISHER, T. A. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-6-1474 · Cited by 77
ChwaliszC. Mattia-Goldberg, K., Lee, M., Elger, W., & Edmonds, A. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.07.212 · Cited by 43
Cited by
Progesterone action in breast, uterine, and ovarian cancers
Diep, C. H., Daniel, A. R., Mauro, L. J., Knutson, T. P., & Lange, C. A. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0252 · Cited by 190
Huniadi, C. A., Pop, O. L., Antal, T. A., & Stamatian, F. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.03.022 · Cited by 35
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
“Results derived from a randomized clinical trial comparing different dosages of asoprisnil, one of the most extensively investigated SPRM, indicate that a daily dose of 5 mg effectively relieves pain associated to endometriosis while only minimally influencing the bleeding pattern [61] .”
BackgroundMifepristone 2.5, 5, 10mg versus placebo in the treatment of endometriosis
Carbonell, J. L., Riverón, A. M., Leonard, Y., González, J., Heredia, B., & Sánchez, C. (2016) · Journal of Reproductive Health and Medicine · doi:10.1016/j.jrhm.2015.09.001 · Cited by 25
Metadata
- Authors
- Spitz, I. M.
- Venue
- Methods and Principles in Medicinal Chemistry
- Publisher
- Wiley
- Published
- 2008-08-20
- Volume
- 7
- Issue
- 10
- Pages
- 223-248
- ISSN
- 1432-4636 (ISSN-L)
- 1865-0562
- OpenAlex
- W1586557470
- Cited by
- 50
- References
- 5
- Type
- other
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progesterone Receptor Antagonists. https://app.cochat.ai/papers/10.1002/9783527623297.ch7
- The paper
- Spitz, I. M. (2008). Progesterone Receptor Antagonists. Methods and Principles in Medicinal Chemistry. https://doi.org/10.1002/9783527623297.ch7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.